GANX · Gain Therapeutics, Inc.

Gain Therapeutics’ Q1 2026 financial results reflect continued investment in clinical advancement, particularly for GT-02287, its lead allosteric GCase modulator for Parkinson’s disease. R&D expenses increased 22% year-over-year to $2.8 million, primarily driven by Phase 1b extension activities, foreign exchange headwinds (Swiss franc and Australian dollar strengthening), and higher personnel costs. G&A expenses rose 24% to $2.6 million, similarly impacted by FX and elevated professional and personnel expenses. Despite a $1.1 million increase in absolute net loss, net loss per share improved to $0.13 from $0.16 due to a 47% increase in weighted average shares outstanding (42.2M vs 28.7M), reflecting dilution from prior financings. Cash declined by $4.3 million quarter-over-quarter to $16.5 million — consistent with the $5.4 million net loss and $0.2 million net foreign exchange loss — positioning the company to fund operations into Q3 2026, assuming IND clearance and Phase 2 initiation occur as guided. Management emphasized durable MDS-UPDRS scores and an 81% mean reduction in CSF glucosylsphingosine — a key lysosomal biomarker — supporting GT-02287’s disease-modifying hypothesis. With FDA IND clearance anticipated in Q2 and Phase 2 slated for Q3, the near-term catalysts are regulatory and clinical, not financial. The absence of revenue, gross margin, or operating income metrics underscores the company’s pre-commercial, clinical-stage status, where expense trends and cash runway are primary investor considerations.